GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated December 23, 2024, serves as a transaction notification for the month of December 2024. The document discloses share purchases made by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It strictly reports on specific equity transactions.
Material Changes and Transactions
The filing details multiple share purchase transactions executed on December 20, 2024, by various directors and a PCA. All transactions were purchases, indicating insider confidence.
- Lady Susan Symonds (PCA of Non-Executive Chair): Purchased 1,500 Ordinary Shares at £13.1508 on the London Stock Exchange.
- Wendy Becker (Independent Non-Executive Director): Purchased 546 Ordinary Shares at £13.1900 on the London Stock Exchange.
- Elizabeth (Liz) McKee Anderson (Independent Non-Executive Director): Purchased 272 ADSs at $33.8097 on the New York Stock Exchange.
- Charles Bancroft (Senior Independent Non-Executive Director): Purchased 2,184 ADSs at $33.8097 on the New York Stock Exchange.
- Dr. Hal Barron (Non-Executive Director): Purchased 271 ADSs at $33.8097 on the New York Stock Exchange.
- Dr. Anne Beal (Independent Non-Executive Director): Purchased 271 ADSs at $33.8097 on the New York Stock Exchange.
- Dr. Hal Dietz (Independent Non-Executive Director): Purchased 271 ADSs at $33.8097 on the New York Stock Exchange.
- Dr. Jesse Goodman (Independent Non-Executive Director): Purchased 271 ADSs at $33.8097 on the New York Stock Exchange.
- Dr. Jeannie Lee (Independent Non-Executive Director): Purchased 271 ADSs at $33.8097 on the New York Stock Exchange.
- Dr. Vishal Sikka (Independent Non-Executive Director): Purchased 937 ADSs at $33.8097 on the New York Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity only.
Key Facts for Investor Verification
- Transaction Date: All reported transactions occurred on December 20, 2024.
- Transaction Type: All reported activities were purchases of company equity (Ordinary Shares or ADSs).
- Participants: The transactions involved the PCA of the Chair and nine Independent or Non-Executive Directors.
- Exchange Locations: Transactions were split between the London Stock Exchange (Ordinary Shares) and the New York Stock Exchange (ADSs).
- Price Consistency: ADS purchases were executed at a uniform price of $33.8097.